Berzosertib

Generic Name
Berzosertib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H25N5O3S
CAS Number
1232416-25-9
Unique Ingredient Identifier
L423PRV3V3
Background

Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

First Posted Date
2022-02-18
Last Posted Date
2024-11-22
Lead Sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Target Recruit Count
6
Registration Number
NCT05246111
Locations
🇭🇺

Magyar Honvédség Egészségügyi Központ, Podmaniczky utcai telephely, Onkológiai Osztály, Budapest, Hungary

🇭🇺

PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

First Posted Date
2021-04-01
Last Posted Date
2024-12-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
120
Registration Number
NCT04826341
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

First Posted Date
2021-03-17
Last Posted Date
2024-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
120
Registration Number
NCT04802174
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

Phase 2
Completed
Conditions
Small-cell Lung Cancer
Interventions
Drug: Berzosertib
Drug: Topotecan
First Posted Date
2021-02-24
Last Posted Date
2023-08-15
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Target Recruit Count
76
Registration Number
NCT04768296
Locations
🇺🇸

National Cancer Institute, Bethesda, Maryland, United States

🇺🇸

FirstHealth of the Carolinas, Inc., Pinehurst, North Carolina, United States

🇺🇸

Summa Health, Akron, Ohio, United States

and more 48 locations

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

First Posted Date
2020-02-12
Last Posted Date
2024-08-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
25
Registration Number
NCT04266912
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

First Posted Date
2020-01-02
Last Posted Date
2024-07-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
12
Registration Number
NCT04216316
Locations
🇺🇸

UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States

🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

🇺🇸

USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States

and more 31 locations

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

First Posted Date
2019-08-12
Last Posted Date
2024-11-15
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
42
Registration Number
NCT04052555
Locations
🇺🇸

University of Texas Medical Branch, Galveston, Texas, United States

🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Farmington Health Center, Farmington, Utah, United States

and more 11 locations

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

First Posted Date
2019-04-01
Last Posted Date
2024-12-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
104
Registration Number
NCT03896503
Locations
🇺🇸

HaysMed, Hays, Kansas, United States

🇺🇸

University Health Truman Medical Center, Kansas City, Missouri, United States

🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

and more 30 locations

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

First Posted Date
2018-08-22
Last Posted Date
2024-12-11
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
14
Registration Number
NCT03641313
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

and more 28 locations

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

First Posted Date
2018-05-08
Last Posted Date
2024-11-15
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
130
Registration Number
NCT03517969
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 20 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy